Navigation Links
AVI BioPharma Reports Positive Pre-Clinical Influenza Data

e. These include three subtypes that caused pandemics in the 20th century -- the 1918 Spanish flu (H1N1), the 1957 Asian flu (H2N2) and the 1968 Hong Kong flu (H3N2) -- and three subtypes of avian flu that have been reported to cause disease in humans (H5N1, H7N7 and H9N2). AVI's potential treatment for seasonal influenza A will be made available to potential licensees.

About Influenza A Viruses

Influenza, or flu, is a contagious respiratory illness caused by influenza viruses. On average 5 percent to 20 percent of the U.S. population is infected with the flu each year. Influenza A virus is an enveloped negative-strand RNA virus, with eight genome segments that code for 10 proteins. Influenza strains are subtyped according to the antigenic and genetic nature of their surface glycoproteins: hemagglutinin (HA or H) and neuraminidase (NA or N). Fifteen H and nine N subtypes have been identified, with three associated with widespread human disease (H1N1, H2N2 and H3N2). In addition, several subtypes of avian influenza virus -- H5N1, H7N7 and H9N2 -- can infect and cause disease in humans.

The current influenza pandemic in birds throughout Asia, Eastern Europe and Turkey is caused by the H5N1 subtype. It is thought that co-infection of humans or certain animals (such as pigs) with both H1N1 and H5N1 can lead to a reassortment or recombination of viral particles, resulting in the emergence of a virus with dangerous public health properties, namely one to which the human population has no natural immunity and which has the ability to spread easily from person to person. It is believed that emergence of avian flu by this general mechanism may have led to the worldwide pandemics of 1918, 1957 and 1968.

About AVI BioPharma

AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NEUGENE antisense drugs and ESPRIT exon skipping technology. AVI's lead NEUGENE antisense compound is design
'"/>




Page: 1 2 3

Related medicine technology :

1. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
2. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
3. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
4. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
5. Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory Drugs
6. PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week
7. Helix BioPharma Corp. Announces Positive Phase II Clinical Results with its Topical Interferon Alpha-2b
8. CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third Generation RIMA Antidepressant
9. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
10. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
11. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: AVI BioPharma Reports Positive Pre Clinical Influenza Data
(Date:9/16/2014)... -- The Lupus Foundation of America and Eli Lilly ... results from UNVEIL: understanding the impact of lupus, a ... and the challenges not only for those living with ... which involved over 1,000 people with lupus and lupus ... aspects of life including family, work, finances, treatment experiences ...
(Date:9/16/2014)... -- Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY ), ... and novel medicines to physicians and patients at accessible ... Baum will be a presenter at the 5 ... York City.  Mr. Baum will discuss the company,s growth ... ophthalmology. The presentation is scheduled for 10:40 a.m. EST on ...
(Date:9/16/2014)... 16, 2014  Relmada Therapeutics, Inc., (OTCBB: RLMD), a ... chronic pain, announced today that it has entered into ... in a series of animal studies for levorphanol, the ... release form of levorphanol.  Gavril Pasternak, MD, PhD, of ... Dr. Pasternak said, "Levorphanol is a unique ...
Breaking Medicine Technology:"UNVEIL" Survey Reveals a Life Interrupted by Lupus 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 3"UNVEIL" Survey Reveals a Life Interrupted by Lupus 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 5Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 2Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 3Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 4Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 2Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 3
(Date:9/16/2014)... use among teens in the United States is on the ... the new study also found that alcohol use, binge drinking ... the ages of 12 and 17 also dropped between 2002 ... 12 and older across the United States revealed that between ... age group also dropped from 8.9 percent to 5.2 percent. ...
(Date:9/16/2014)... equally preserved in cancer patients suffering from malignant spinal ... 10 Gy of radiation therapy (RT), compared to patients ... RT each, according to research presented today at the ... , Malignant spinal cord compression (MSCC) is a ... occurs when a tumor,s secondary deposit presses on the ...
(Date:9/16/2014)... to be on the heavy side. Researchers at the ... seven in every ten obese adults underestimate how much ... much less often. Mothers of overweight or obese children ... misjudge their obese mothers, size, says lead author Tracy ... in the Journal of General Internal Medicine , ...
(Date:9/16/2014)... -- While abnormalities in the adrenergic and noradrenergic ... thought to play a role in the development ... has been no genetic evidence of this connection. ... Columbia University,s Mailman School of Public Health and ... the ADRB2 gene and childhood adversity. For individuals ...
(Date:9/16/2014)... The Pain Center of Arizona (TPC), ... has selected Analance ™, Ducen ’s BI ... TPC seeing hundreds of thousands of patients annually, the ... through “home grown” systems trying to piece together actionable ... “Our current tools were not scalable and, in ...
Breaking Medicine News(10 mins):Health News:Fewer U.S. Teens Using Illegal Drugs and Alcohol, Report Finds 2Health News:Cancer patients with malignant spinal cord compression have preserved mobility 2Health News:Cancer patients with malignant spinal cord compression have preserved mobility 3Health News:Cancer patients with malignant spinal cord compression have preserved mobility 4Health News:Poor body size judgement can lead to increased tolerance of obesity 2Health News:Evidence of genetic link to PTSD in soldiers exposed to childhood trauma 2Health News:Evidence of genetic link to PTSD in soldiers exposed to childhood trauma 3Health News:The Pain Center of Arizona (TPC) Implements Analance™ BI for Actionable Intelligence 2Health News:The Pain Center of Arizona (TPC) Implements Analance™ BI for Actionable Intelligence 3
... leading neuromodulation company, announced today that beginning January ... by Medicare for incomplete spinal cord injury patients ... Centers for Medicare and Medicaid Services (CMS) establishes ... stimulation (FES) devices including the NESS L300™ Foot ...
... changed in a heartbeat for successful freelance writer Lee Woodruff ... Tonight, was wounded while broadcasting from Iraq. Her experience as ... be the focus of her keynote address at URAC,s Best ... Exhibit, April 1-2, 2009 in Orlando, Fla. , ...
... 11 Rosalind Franklin University,of Medicine and Science ... the first in the nation to provide its students with ... The new,system enables medical educators to present students with individual ... has a proven,accuracy rate of over 90 percent. , ...
... Pain Therapeutics, Inc. (Nasdaq: PTIE ) has received a ... for its New Drug Application (NDA) for REMOXY(R), an abuse-resistant controlled-release ... determined that the NDA is not approved in its present form. ... believes additional non-clinical data will be required to support the approval ...
... 11 Preferred Management Corporation of,Shawnee, OK ... two hospitals near Amarillo, Texas. The hospitals, ... General Hospital in Wellington, are both,federally designated ... are administered by Preferred Management Corporation which ...
... to be ignoring message that methamphetamine is dangerous , , ... that utilizes graphic images actually may not be very ... Project (MMP), created in 2005, featured images that showed ... perceived success of the program had resulted in its ...
Cached Medicine News:Health News: Medicare to Reimburse for the Bioness L300™ Foot Drop System for Spinal Cord Injury 2Health News: Medicare to Reimburse for the Bioness L300™ Foot Drop System for Spinal Cord Injury 3Health News:Best-selling Author Lee Woodruff, Futurist Ian Morrison to Speak at URAC's Best Practices Conference 2Health News:Best-selling Author Lee Woodruff, Futurist Ian Morrison to Speak at URAC's Best Practices Conference 3Health News:Rosalind Franklin University of Medicine and Science First in Illinois to Equip Students With Computerized Diagnosis System 2Health News:Pain Therapeutics Receives Complete Response Letter From FDA for REMOXY(R) 2Health News:Pain Therapeutics Receives Complete Response Letter From FDA for REMOXY(R) 3Health News:Preferred Management Corp. Installs OpusClinicalSuite(R) at 2 Texas Hospitals 2Health News:Preferred Management Corp. Installs OpusClinicalSuite(R) at 2 Texas Hospitals 3Health News:Study Questions Value of Anti-Meth Campaign 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: